Abstract
The genetic alterations associated with breast carcinogenesis are well known. On the contrary epigenetic alterations in hereditary breast cancer are a new field. Two epigenetic mechanisms have emerged as the most critical players in transcriptional regulation in breast cancer: the methylation of DNA and microRNA interference.
In this review we will focus on recent findings on gene silencing caused by DNA methylation and microRNA to explore the potential role of these epigenetic changes in the understanding of hereditary breast cancer. Moreover we will describe the same alterations in basal-like breast cancer and in triple-negative breast cancer, since their phenotypes have similarities with BRCA1-mutated tumors. To underline the possibility that some epigenetic alterations could also be used as potential epigenetic biomarkers of drug sensitivity or resistance, we will discuss the more common therapies in hereditary breast cancer that could also be applied to breast cancer with basal-like or triple negative phenotypes.
Keywords: Basal-like breast cancer, BRCA1, hereditary breast cancer, methylation, miRNA, triple-negative breast cancer.
Current Molecular Medicine
Title:DNA Methylation and miRNAs Regulation in Hereditary Breast Cancer: Epigenetic Changes, Players in Transcriptional and Post- Transcriptional Regulation in Hereditary Breast Cancer
Volume: 14 Issue: 1
Author(s): R. Pinto, S. De Summa, B. Pilato and S. Tommasi
Affiliation:
Keywords: Basal-like breast cancer, BRCA1, hereditary breast cancer, methylation, miRNA, triple-negative breast cancer.
Abstract: The genetic alterations associated with breast carcinogenesis are well known. On the contrary epigenetic alterations in hereditary breast cancer are a new field. Two epigenetic mechanisms have emerged as the most critical players in transcriptional regulation in breast cancer: the methylation of DNA and microRNA interference.
In this review we will focus on recent findings on gene silencing caused by DNA methylation and microRNA to explore the potential role of these epigenetic changes in the understanding of hereditary breast cancer. Moreover we will describe the same alterations in basal-like breast cancer and in triple-negative breast cancer, since their phenotypes have similarities with BRCA1-mutated tumors. To underline the possibility that some epigenetic alterations could also be used as potential epigenetic biomarkers of drug sensitivity or resistance, we will discuss the more common therapies in hereditary breast cancer that could also be applied to breast cancer with basal-like or triple negative phenotypes.
Export Options
About this article
Cite this article as:
Pinto R., Summa De S., Pilato B. and Tommasi S., DNA Methylation and miRNAs Regulation in Hereditary Breast Cancer: Epigenetic Changes, Players in Transcriptional and Post- Transcriptional Regulation in Hereditary Breast Cancer, Current Molecular Medicine 2014; 14 (1) . https://dx.doi.org/10.2174/1566524013666131203101405
DOI https://dx.doi.org/10.2174/1566524013666131203101405 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Hot Topic: Ductal Carcinoma in situ (DCIS) of the Breast, Biomarkers, Diagnosis, and Treatment of the Disease)
Current Cancer Therapy Reviews The Molecular Bases of the Self-Renewal and Differentiation of Leukemic Stem Cells
Current Cancer Therapy Reviews Anticancer Potential of Pulicaria crispa Extract on Human Breast Cancer MDA-MB-231 Cells
Letters in Drug Design & Discovery ZD6474, a Small Molecule Tyrosine Kinase Inhibitor, Potentiates the Anti-Tumor and Anti-Metastasis Effects of Radiation for Human Nasopharyngeal Carcinoma
Current Cancer Drug Targets Omega – 3 Fatty Acids as Pharmacotherapeutics in Psoriasis: Current Status and Scope of Nanomedicine in its Effective Delivery
Current Drug Targets VEGF Signal System: The Application of Antiangiogenesis
Current Medicinal Chemistry The High Throughput Biomedicine Unit at the Institute for Molecular Medicine Finland: High Throughput Screening Meets Precision Medicine
Combinatorial Chemistry & High Throughput Screening Stem Cells Therapies in Basic Science and Translational Medicine: Current Status and Treatment Monitoring Strategies
Current Pharmaceutical Biotechnology Antileukotriene Drugs: Clinical Application, Effectiveness and Safety
Current Medicinal Chemistry Platinum-Based Agents for Individualized Cancer Treatment
Current Molecular Medicine From the Deepest Sea Shelf to the Uppermost Kitchen Cabinet Shelf: The Quest for Novel TNF-α Inhibitors
Current Topics in Medicinal Chemistry Palladium-Catalyzed Oxyarylation, Azaarylation and α-Arylation Reactions in the Synthesis of Bioactive Isoflavonoid Analogues
Current Organic Synthesis The Detrimental Effect of Smoking on Female Fertility and IVF Success
Current Women`s Health Reviews Study About the Knowledge and Attitudes of the Portuguese Population About Food Fibres
Current Nutrition & Food Science Cell Metabolism Under Microenvironmental Low Oxygen Tension Levels in Stemness, Proliferation and Pluripotency
Current Molecular Medicine Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry Towards the Development of Tumor Necrosis Factor (TNF) Sensitizers:Making TNF Work Against Cancer
Current Pharmaceutical Design PET Imaging of Beta-Adrenoceptors in Human Brain: A Realistic Goal or a Mirage?
Current Pharmaceutical Design Opioid Analgesics and P-Glycoprotein Efflux Transporters: A Potential Systems-Level Contribution to Analgesic Tolerance
Current Topics in Medicinal Chemistry Medicinal Properties of Neem Leaves: A Review
Current Medicinal Chemistry - Anti-Cancer Agents